These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31692898)

  • 1. Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.
    Boswell CA; Yadav DB; Mundo EE; Yu SF; Lacap JA; Fourie-O'Donohue A; Kozak KR; Ferl GZ; Zhang C; Ho J; Ulufatu S; Khawli LA; Lin K
    Oncotarget; 2019 Oct; 10(58):6234-6244. PubMed ID: 31692898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.
    Boswell CA; Mundo EE; Zhang C; Stainton SL; Yu SF; Lacap JA; Mao W; Kozak KR; Fourie A; Polakis P; Khawli LA; Lin K
    J Nucl Med; 2012 Sep; 53(9):1454-61. PubMed ID: 22872740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1.
    Williams SP; Ogasawara A; Tinianow JN; Flores JE; Kan D; Lau J; Go M; Vanderbilt AN; Gill HS; Miao L; Goldsmith J; Rubinfeld B; Mao W; Firestein R; Yu SF; Marik J; Terwisscha van Scheltinga AG
    Oncotarget; 2016 May; 7(18):25103-12. PubMed ID: 27029064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.
    Boswell CA; Mundo EE; Firestein R; Zhang C; Mao W; Gill H; Young C; Ljumanovic N; Stainton S; Ulufatu S; Fourie A; Kozak KR; Fuji R; Polakis P; Khawli LA; Lin K
    Br J Pharmacol; 2013 Jan; 168(2):445-57. PubMed ID: 22889168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
    Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
    Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence.
    Glynne-Jones E; Harper ME; Seery LT; James R; Anglin I; Morgan HE; Taylor KM; Gee JM; Nicholson RI
    Int J Cancer; 2001 Oct; 94(2):178-84. PubMed ID: 11668495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.
    Chang HP; Le HK; Shah DK
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
    Bhaskar V; Law DA; Ibsen E; Breinberg D; Cass KM; DuBridge RB; Evangelista F; Henshall SM; Hevezi P; Miller JC; Pong M; Powers R; Senter P; Stockett D; Sutherland RL; von Freeden-Jeffry U; Willhite D; Murray R; Afar DE; Ramakrishnan V
    Cancer Res; 2003 Oct; 63(19):6387-94. PubMed ID: 14559828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated matriptase as a target to treat breast cancer with a drug conjugate.
    Rather GM; Lin SY; Lin H; Banach-Petrosky W; Hirshfield KM; Lin CY; Johnson MD; Szekely Z; Bertino JR
    Oncotarget; 2018 May; 9(40):25983-25992. PubMed ID: 29899836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
    Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
    Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody.
    Buchsbaum DJ; Wahl RL; Glenn SD; Normolle DP; Kaminski MS
    Cancer Res; 1992 Feb; 52(3):637-42. PubMed ID: 1732052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacologic basis for antibody-auristatin conjugate activity.
    Alley SC; Zhang X; Okeley NM; Anderson M; Law CL; Senter PD; Benjamin DR
    J Pharmacol Exp Ther; 2009 Sep; 330(3):932-8. PubMed ID: 19498104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Drug Conjugate to Treat Meningiomas.
    Chen K; Si Y; Ou J; Guan JS; Kim S; Ernst P; Zhang Y; Zhou L; Han X; Liu XM
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34063284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.
    Sedlik C; Heitzmann A; Viel S; Ait Sarkouh R; Batisse C; Schmidt F; De La Rochere P; Amzallag N; Osinaga E; Oppezzo P; Pritsch O; Sastre-Garau X; Hubert P; Amigorena S; Piaggio E
    Oncoimmunology; 2016 Jul; 5(7):e1171434. PubMed ID: 27622021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.